CASE REPORT article
Front. Oncol.
Sec. Hematologic Malignancies
This article is part of the Research TopicCase-based Advances in the Understanding of Rare and Unusual Hematologic Malignancies 2025-2026View all 18 articles
Deceptive Initial Presentation of Systemic DLBCL with CNS Progression Following Oligometabolic PET/CT: Case Report
Provisionally accepted
- Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
We present a diagnostically challenging case of a 51-year-old woman with systemic diffuse large B-cell lymphoma (DLBCL) that progressed to secondary central nervous system (CNS) involvement. The initial presentation was notable for a whole-body PET/CT scan showing only subtle, diffuse fluorodeoxyglucose uptake in lymph nodes and bone marrow (SUVmax <5.0), below conventional thresholds for malignancy. Four months later, the patient developed an acute encephalopathic illness accompanied by multiorgan dysfunction and a severe hyperinflammatory state consistent with hemophagocytic lymphohistiocytosis. Hallmark laboratory features included refractory lactic acidosis, extreme hyperferritinemia, markedly elevated lactate dehydrogenase, and profound CD4+ lymphopenia. Cranial imaging revealed rapidly progressive, non‑specific parenchymal lesions. A definitive diagnosis of the non‑germinal center B‑cell (non‑GCB) subtype of DLBCL was secured via biopsy of a readily accessible facial lymph node—rather than high‑risk brain biopsy—illustrating a pivotal diagnostic principle. This case highlights that unexplained persistent lactic acidosis, extreme hyperferritinemia, and even subthreshold PET/CT findings can be sentinel signs of an underlying aggressive lymphoma. It emphasizes the need for high clinical suspicion and the pursuit of safe, extracranial biopsy sites to enable early diagnosis and intervention in such diagnostically elusive cases.
Keywords: Diffuse large B-cell lymphoma, Immunohistochemistry, non-GCB subtype, PET/CT, secondary CNS lymphoma
Received: 30 Oct 2025; Accepted: 12 Feb 2026.
Copyright: © 2026 Yuan, Yu, Chen, Long and Gao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Peiyang Gao
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.